12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zalypsis: Phase II discontinued

PharmaMar discontinued a Phase II trial after data from 19 evaluable patients in the first stage of the trial showed that 3 mg/m 2 IV Zalypsis every 3 weeks did not meet the pre-specified threshold of at least 4 of 17 patients achieving...

Read the full 195 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >